HWAM
MLYS icon

Hennion & Walsh Asset Management’s Mineralys Therapeutics MLYS Stock Holding History

Hennion & Walsh Asset Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.88M Sell
69,580
-609
-0.9% -$16.7K 0.05% 395
2026
Q1 		$1.9M Buy
70,189
+827
+1% +$24.3K 0.06% 364
2025
Q4 		$2.52M Buy
69,362
+16,514
+31% +$662K 0.09% 299
2025
Q3 		$2M Buy
52,848
+21,753
+70% +$471K 0.07% 347
2025
Q2 		$421K Buy
+31,095
New +$451K 0.02% 725

Other funds holding MLYS

AP
Andera Partners Paris $206M AUM
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
EC
Eleva Capital Paris, France $343M AUM
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return

Hennion & Walsh Asset Management's MLYS Position: Q2 2026 in Review

Hennion & Walsh Asset Management reduced its Mineralys Therapeutics (MLYS) stake by 0.87% in Q2 2026, selling an estimated $16.7K and leaving 69,580 shares worth $1.88M. The position accounts for 0.05% of the portfolio, ranked #395.

Hennion & Walsh Asset Management first reported a position in MLYS in Q2 2025 and has held it in 5 quarters since. The position peaked at $2.52M in Q4 2025. 19 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Hennion & Walsh Asset Management held 69,580 shares of Mineralys Therapeutics worth $1.88M as of Q2 2026.
  • Hennion & Walsh Asset Management sold 609 Mineralys Therapeutics shares in Q2 2026, an estimated $16.7K.
  • Mineralys Therapeutics made up 0.05% of Hennion & Walsh Asset Management's portfolio in Q2 2026, its #395 holding.
  • Hennion & Walsh Asset Management first reported a position in Mineralys Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Hennion & Walsh Asset Management's Mineralys Therapeutics position peaked at $2.52M in Q4 2025.
  • 19 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.